Story
Ionis Pharmaceuticals Stock Climbs After Q2 Revenue and Earnings Crush Estimates
Ionis Pharmaceuticals (NASDAQ: IONS) shares gained ground in pre-market trading after the company announced second-quarter earnings and revenue that substantially exceeded Wall Street forecasts. The strong performance offers a counter-narrative to the stock's recent weakness, which was triggered by a disappointing clinical trial result earlier in the month.
Second-Quarter Outperformance
The RNA-targeted drug developer reported a second-quarter loss of $0.69 per share, a figure significantly narrower than the consensus analyst estimate for a loss between $1.06 and $1.10 per share. Top-line results were also robust, with revenue coming in at $268 million, easily surpassing expectations that ranged from approximately $187 million to $190 million.
This revenue beat suggests the commercial launch of its drug Tryngolza (olezarsen) may be gaining traction more quickly than anticipated. The result is particularly noteworthy given the company's significant price reduction for the treatment ahead of its broader market approval.
Rebound from Trial Setback
AdThe positive earnings report provides a much-needed catalyst for the stock, which has been under heavy selling pressure since July 9. On that date, Ionis and its partner AstraZeneca announced that the Phase 3 CARDIO-TTRansform study of their drug eplontersen failed to meet its primary efficacy endpoint, causing the stock to fall by roughly 23% in a single session.
Today's decisive earnings beat appears to be prompting investors to look beyond the eplontersen trial failure and re-evaluate the company's commercial strength and pipeline depth. The stock rose 2.4% to $56.65 in pre-open trading, supported by a modestly positive broader market.
Analyst Perspective
Heading into the earnings announcement, the analyst community had largely maintained a bullish outlook on Ionis despite the recent trial news. The consensus rating on the stock remains a "Buy," with an average 12-month price target near $92.95, according to Investing.com. This reflects underlying confidence in the company's broader portfolio of drug candidates.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.
Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.
Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.
DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.